AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
NeoGenomics Wins Patent Infringement Lawsuit Against Natera, RaDaR ST Assay Cleared for Market
ByAinvest
Saturday, Aug 30, 2025 5:53 pm ET1min read
NeoGenomics has won a patent infringement lawsuit against Natera, with the court invalidating Natera's patents. This allows NeoGenomics to freely market its RaDaR ST assay. The company is seeking CMS reimbursement coverage for the assay. NeoGenomics CEO Tony Zook expressed satisfaction with the court's decision, emphasizing the company's commitment to offering comprehensive diagnostic testing options for cancer patients.
NeoGenomics, Inc. (NEO) has secured a significant legal victory, as the District Court for the Middle District of North Carolina invalidated all of Natera Inc.'s (NTRA) asserted patent claims in a patent infringement case. This ruling allows NeoGenomics to freely market its RaDaR ST assay, a diagnostic tool for cancer patients [1].The court's decision in favor of NeoGenomics marks a turning point for the company, which has been under investigation for potential securities fraud and has reported substantial financial setbacks [2]. Despite these challenges, the patent victory is expected to enhance NeoGenomics' market position and revenue streams.
NeoGenomics' CEO Tony Zook expressed satisfaction with the court's decision, emphasizing the company's commitment to offering comprehensive diagnostic testing options for cancer patients [3]. The company is now seeking CMS reimbursement coverage for the RaDaR ST assay, which could further boost its financial health and market standing.
Analysts at Needham & Company have maintained a Buy rating for NeoGenomics while raising the price target (PT) for the company's stock to $14 from $8. This update reflects the potential long-term benefits of the patent victory, despite the ongoing investigation for potential securities fraud [4].
Investors should closely monitor the situation, as the company's recent patent victory could provide a boost to its market position and revenue streams. However, the ongoing investigation for potential securities fraud remains a significant challenge [5].
References:
[1] https://www.ainvest.com/news/neogenomics-shares-rise-18-59-premarket-court-invalidates-natera-patents-2508/
[2] https://www.ainvest.com/news/neogenomics-needham-buy-rating-raises-pt-14-8-2508/
[3] https://www.marketwatch.com/investing/stock/neo
[4] https://seekingalpha.com/news/4490420-neogenomics-stock-up-court-win-natera
[5] https://www.investing.com/news/analyst-ratings
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet